Aligos Therapeutics (ALGS) Operating Income (2021 - 2025)
Historic Operating Income for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$28.4 million.
- Aligos Therapeutics' Operating Income fell 4088.22% to -$28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.7 million, marking a year-over-year increase of 830.34%. This contributed to the annual value of -$89.2 million for FY2024, which is 116.54% down from last year.
- Aligos Therapeutics' Operating Income amounted to -$28.4 million in Q3 2025, which was down 4088.22% from -$18.6 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Operating Income ranged from a high of -$18.6 million in Q2 2025 and a low of -$37.9 million during Q4 2021
- In the last 5 years, Aligos Therapeutics' Operating Income had a median value of -$22.7 million in 2022 and averaged -$24.7 million.
- Per our database at Business Quant, Aligos Therapeutics' Operating Income skyrocketed by 4269.99% in 2022 and then plummeted by 4088.22% in 2025.
- Quarter analysis of 5 years shows Aligos Therapeutics' Operating Income stood at -$37.9 million in 2021, then surged by 40.23% to -$22.7 million in 2022, then fell by 14.62% to -$26.0 million in 2023, then rose by 20.9% to -$20.6 million in 2024, then tumbled by 37.92% to -$28.4 million in 2025.
- Its Operating Income stands at -$28.4 million for Q3 2025, versus -$18.6 million for Q2 2025 and -$19.2 million for Q1 2025.